12 Month Price Forecast For LIVN
Distance to LIVN Price Forecasts
LIVN Price Momentum
🤔 Considering LivaNova (LIVN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 10:21 AM UTC
LIVN Analyst Ratings & Price Targets
Based on our analysis of 13 Wall Street analysts, LIVN has a bullish consensus with a median price target of $70.00 (ranging from $53.00 to $90.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $48.51, the median forecast implies a 44.3% upside. This outlook is supported by 8 Buy, 3 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LIVN Analyst Consensus
LIVN Price Target Range
Latest LIVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LIVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 28, 2025 | Needham | Mike Matson | Buy | Reiterates | $75.00 |
| Nov 25, 2024 | Needham | Mike Matson | Buy | Reiterates | $75.00 |
| Nov 12, 2024 | Needham | Mike Matson | Buy | Reiterates | $75.00 |
| Oct 31, 2024 | Mizuho | Anthony Petrone | Outperform | Maintains | $70.00 |
| Oct 31, 2024 | Needham | Mike Matson | Buy | Reiterates | $75.00 |
| Oct 31, 2024 | Baird | David Rescott | Outperform | Maintains | $72.00 |
| Oct 4, 2024 | Goldman Sachs | David Roman | Buy | Initiates | $65.00 |
| Sep 17, 2024 | Baird | David Rescott | Outperform | Upgrade | $66.00 |
| Aug 28, 2024 | Baird | Mike Polark | Neutral | Maintains | $55.00 |
| Aug 1, 2024 | Baird | Mike Polark | Neutral | Maintains | $55.00 |
| Jul 31, 2024 | Needham | Mike Matson | Buy | Maintains | $75.00 |
| Jul 25, 2024 | Stifel | Rick Wise | Buy | Maintains | $72.00 |
| Jun 6, 2024 | Needham | Mike Matson | Buy | Reiterates | $72.00 |
| May 2, 2024 | Baird | Mike Polark | Neutral | Maintains | $66.00 |
| May 2, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $80.00 |
| May 1, 2024 | Needham | Mike Matson | Buy | Reiterates | $72.00 |
| Mar 27, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $75.00 |
| Mar 20, 2024 | Needham | Mike Matson | Buy | Reiterates | $72.00 |
| Feb 27, 2024 | Barclays | Matt Miksic | Equal-Weight | Maintains | $61.00 |
| Feb 26, 2024 | Barclays | Matt Miksic | Equal-Weight | Maintains | $61.00 |
Stocks Similar to LivaNova PLC
The following stocks are similar to LivaNova based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LivaNova PLC (LIVN) Financial Data
LivaNova PLC has a market capitalization of $2.61B with a P/E ratio of 111.6x. The company generates $1.24B in trailing twelve-month revenue with a 1.9% profit margin.
Revenue growth is +11.2% quarter-over-quarter, while maintaining an operating margin of +14.1% and return on equity of +1.9%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
LivaNova PLC (LIVN) Company Overview
About LivaNova PLC
Develops and sells medical therapeutic solutions.
LivaNova operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. It generates revenue by designing, manufacturing, and selling a range of medical devices, including heart-lung machines and VNS Therapy Systems, primarily targeting healthcare providers and medical institutions through direct sales and independent distributors.
Incorporated in 2015 and headquartered in London, LivaNova focuses on innovative solutions for critical health conditions, serving a diverse clientele including perfusionists and neurologists. The company's product offerings address complex medical needs, positioning it favorably within the healthcare market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
2,900
CEO
Mr. Vladimir A. Makatsaria
Country
United Kingdom
IPO Year
2015
Website
www.livanova.comLivaNova PLC (LIVN) Latest News & Analysis
LivaNova PLC will host a conference call on February 25, 2025, at 1 p.m. London time to discuss its Q4 and full-year 2024 results, with results released prior to the call.
LivaNova's upcoming earnings call will provide insights into its financial performance, influencing market perceptions and potential stock movement.
Investors are advised to consider discounted stocks, including MCK, HAE, ARAY, LIVN, and PBH, in the current market conditions.
Discounted stocks like MCK, HAE, ARAY, LIVN, and PBH may present buying opportunities, potentially leading to significant returns as market conditions improve.
LivaNova PLC reported that Brain Stimulation published two key articles on the unipolar cohort data from the RECOVER clinical study.
LivaNova's publication of pivotal RECOVER study data could enhance its credibility and attract investment, potentially impacting stock performance and market perception of its cardiac solutions.
LivaNova PLC will participate in the American Epilepsy Society 2024 Annual Meeting from Dec. 6-10 in Los Angeles, highlighting its engagement in the epilepsy sector.
LivaNova's participation in a key medical conference highlights its commitment to innovation in healthcare, potentially impacting its market position and stock performance.
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know
2 months agoAnalysts' price targets for LivaNova (LIVN) suggest a 37.2% upside, supported by increased earnings estimates, indicating potential growth in the stock.
Analysts' price targets suggest significant potential upside for LivaNova (LIVN), indicating positive sentiment and possible stock appreciation, which may attract investor interest.
LIVN's aura6000 device has improved responder rates and decreased AHI and ODI levels, indicating enhanced performance in its medical applications.
LIVN's aura6000 improving responder rates and lowering AHI and ODI suggests stronger market demand and potential revenue growth, positively impacting the company's stock performance.
Frequently Asked Questions About LIVN Stock
What is LivaNova PLC's (LIVN) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, LivaNova PLC (LIVN) has a median price target of $70.00. The highest price target is $90.00 and the lowest is $53.00.
Is LIVN stock a good investment in 2025?
According to current analyst ratings, LIVN has 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $48.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LIVN stock?
Wall Street analysts predict LIVN stock could reach $70.00 in the next 12 months. This represents a 44.3% increase from the current price of $48.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is LivaNova PLC's business model?
LivaNova operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. It generates revenue by designing, manufacturing, and selling a range of medical devices, including heart-lung machines and VNS Therapy Systems, primarily targeting healthcare providers and medical institutions through direct sales and independent distributors.
What is the highest forecasted price for LIVN LivaNova PLC?
The highest price target for LIVN is $90.00 from at , which represents a 85.5% increase from the current price of $48.51.
What is the lowest forecasted price for LIVN LivaNova PLC?
The lowest price target for LIVN is $53.00 from at , which represents a 9.3% increase from the current price of $48.51.
What is the overall LIVN consensus from analysts for LivaNova PLC?
The overall analyst consensus for LIVN is bullish. Out of 13 Wall Street analysts, 8 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $70.00.
How accurate are LIVN stock price projections?
Stock price projections, including those for LivaNova PLC, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
